Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001;2001(1):CD001873.
doi: 10.1002/14651858.CD001873.

Betahistine for Menière's disease or syndrome

A L James  1 , M J Burton
Affiliations

Betahistine for Menière's disease or syndrome

A L James et al. Cochrane Database Syst Rev. 2001.

Abstract

Background: Menière's disease is characterised by attacks of hearing loss, tinnitus and disabling vertigo. Betahistine is used by many people to reduce the frequency and severity of these attacks but there is conflicting evidence relating to its effects.

Objectives: The objective of this review was to assess the effects of betahistine in people with Menière's disease.

Search strategy: We searched the Cochrane Controlled Trials Register (The Cochrane Library issue 4,1999), MEDLINE (January 1966 to December 1999), EMBASE (January 1985 to December 1999) and Index Medicus (1962 to 1966). We checked reference lists of articles and contacted pharmaceutical companies for further studies.

Selection criteria: Randomised controlled studies of betahistine versus placebo in Menière's disease.

Data collection and analysis: Two reviewers independently assessed trial quality and extracted data. Study authors were contacted for further information.

Main results: Six trials involving 162 patients were included. No trial met the highest quality standard set by the review because of inadequate diagnostic criteria or methods, and none assessed the effect of betahistine on vertigo adequately. Most trials suggested a reduction of vertigo with betahistine and some suggested a reduction in tinnitus but all these effects may have been caused by bias in the methods. One trial with good methods showed no effect of betahistine on tinnitus compared with placebo in 35 patients. None of the trials showed any effect of betahistine on hearing loss. No adverse effects were found with betahistine.

Reviewer's conclusions: There is insufficient evidence to say whether betahistine has any effect on Menière's disease.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1: Betahistine versus placebo ‐ number of vertigo attacks, Outcome 1: Vertigo ‐ number of attacks per month at baseline
1.2
1.2. Analysis
Comparison 1: Betahistine versus placebo ‐ number of vertigo attacks, Outcome 2: Vertigo ‐ number of attacks per month at 15 days
1.3
1.3. Analysis
Comparison 1: Betahistine versus placebo ‐ number of vertigo attacks, Outcome 3: Vertigo ‐ number of attacks per month at 1 month
1.4
1.4. Analysis
Comparison 1: Betahistine versus placebo ‐ number of vertigo attacks, Outcome 4: Vertigo ‐ number of attacks per month at 2 months
1.5
1.5. Analysis
Comparison 1: Betahistine versus placebo ‐ number of vertigo attacks, Outcome 5: Vertigo ‐ number of attacks per month at 3 months
2.1
2.1. Analysis
Comparison 2: Betahistine versus placebo ‐ vertigo intensity scores, Outcome 1: Vertigo intensity scores at baseline
2.2
2.2. Analysis
Comparison 2: Betahistine versus placebo ‐ vertigo intensity scores, Outcome 2: Vertigo intensity scores at 15 days
2.3
2.3. Analysis
Comparison 2: Betahistine versus placebo ‐ vertigo intensity scores, Outcome 3: Vertigo intensity scores at 1 month
2.4
2.4. Analysis
Comparison 2: Betahistine versus placebo ‐ vertigo intensity scores, Outcome 4: Vertigo intensity scores at 2 months
2.5
2.5. Analysis
Comparison 2: Betahistine versus placebo ‐ vertigo intensity scores, Outcome 5: Vertigo intensity scores at 3 months
See this image and copyright information in PMC

References

References to studies included in this review

Burkin 1967 {published data only}
    1. Burkin A. Betahistine treatment of Menière's syndrome. Clinical Medicine 1967;74:41-8.
Elia 1966 {published data only}
    1. Elia JC. Double-blind evaluation of a new treatment for Menière's syndrome. JAMA 1966;196:187-9. - PubMed
Mira 2003 {published data only}
    1. Mira E, Guidetti G, Ghilardi L, Fattori B, Malannino N, Maiolino L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. European Archives of Oto-Rhino-Laryngology 2003;260(2):73-7. - PubMed
    1. Mira E. Personal communication 2007.
Okamato 1968 {published data only}
    1. Hayakawa Y. Personal communication 2000.
    1. Okamato K, Hazeyama F, Taira T, Yoshida A. Therapeutic results of betahistine in Menière's disease with statistical analysis. Iryo 1968;22:650-66. - PubMed
Ricci 1987 {published data only}
    1. Ricci V, Sittoni V, Nicora M. Efficacy and safety of betahistine hydrochloride versus placebo in Menière's disease [Valutazione terapeutica e tollerabilita del chloridrato di betaistina (Microser) in confronto a placebo nella malattia di Menière]. Rivista Italiana di Ornitologia Audiologia e Foniatria 1987;7(3):347-50.
Salami 1984 {published and unpublished data}
    1. Salami A, Dellepiane M, Tinelle E, Jankowska B. Double blind study of betahistine and placebo in the treatment of Menière's Syndrome [Studio a doppia cecita' tra cloridrato di betaistina e placebo nel trattamento delle sindromi Menieriformi]. Il Valsalva 1984;60:302-12.
Schmidt 1992 {published data only}
    1. Schmidt JT, Huizing EH. The clinical drug trial in Menière's disease with emphasis on the effect of betahistine SR. Acta Otolaryngologica Supplement 1992;497:1-189. - PubMed

References to studies excluded from this review

Canty 1981 {published data only}
    1. Canty P, Valentine J, Papworth SJ. Betahistine in peripheral vertigo. A double blind placebo controlled cross-over study of Serc versus placebo. Journal of Laryngology and Otology 1981;95:687-92. - PubMed
Conraux 1988 {published data only}
    1. Conraux C. Les sensations vertigineuses chroniques: efficacité de la betahistine prouvée dans un essai therapeutique en double aveugle. Impact Medecin 1988;260:63-5.
Fischer 1985 {published data only}
    1. Fischer AJEM, Elferen LWM. Betahistine bij de behandeling van aanvalsgewijs optredende duizeligheid. Een dubbelblind onderzoek. Tijdschr Ther Geneesm Onderz 1985;10:933-7.
Frew 1976 {published data only}
    1. Frew IJ, Menon GN. Betahistine hydrochloride in Menière's disease. Postgraduate Medical Journal 1976;52:501-3. - PMC - PubMed
Hicks 1967 {published data only}
    1. Hicks JJ, Hicks JN, Cooley HN. Menière's disease. Archives of Otolaryngology 1967;86(6):610-3. - PubMed
Legent 1988 {published data only}
    1. Legent F, Calais C, Cellier D. Vertiges paroxystiques iteratifs et Serc. Étude clinique controlée. Concours Medical 1988;110:2539-43.
Meyer 1985 {published data only}
    1. Meyer ED. Treatment of Menière disease with betahistine dimesilate (Aequamen) - double-blind study versus placebo (crossover) [Zur behandlung des morbus Menière mit betahistindimesilat (Aequamen). Doppelblindstudie gegen plazebo (crossover)]. Laryngologie Rhinologie Otologie 1985;64(5):269-72. - PubMed
Oosterveld 1984 {published data only}
    1. Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. Journal of Laryngology and Otology 1984;98(1):37-41. - PubMed
Oosterveld 1989 {published data only}
    1. Oosterveld WJ, Blijleven W, Elferen LWM. Betahistine versus placebo in paroxysmal vertigo; a double blind trial. Tijdschr Ther Geneesm Onderz 1989;14:122-6.
Redon 2010 {published data only}
    1. Redon C, Lopez C, Bernard-Demanze L, Dumitrescu M, Magnan J, Lacour M, et al. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. Journal of Clinical Pharmacology 2010;[Epub ahead of print]. - PubMed
Singarelli 1979 {published data only}
    1. Singarelli S. Double-blind trial on the efficacy of betahistine hydrochloride in a group of out patients with positional vertigo and tinnitus. Nuovo Archivio Italiano di Otologia Rinologia e Laringologia 1979;Suppl 7:69-72.
Solvay 2007 {published data only}
    1. Solvay Pharmaceuticals. A double-blind, placebo-controlled, randomized, clinical study of the effects of Betaserc® 24 mg (1 tablet b.i.d over 3 months) on vestibular compensation following vestibular neurotomy in patients with disabling Menière's disease. http://ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-2007 (accessed 21 June 2007). [NCT00160238]
Watanabe 1967 {published data only}
    1. Watanabe K, Fukami J, Yoshimoto H, Ueda M, Suzuki J, Okamato M, et al. Evaluation of efficacy of betahistine on patients with vertigo by double blind test and discriminant analysis. Japanese Medical News (Overseas edition) 1967;119:5-8.
    1. Watanabe K, Fukami J, Yoshimoto H, Ueda M, Suzuki J, Okamato M, et al. Evaluation of efficacy of betahistine on patients with vertigo by double blind test and discriminant analysis. Japanese Medical News (Overseas edition) 1967;120:10-1.
    1. Watanabe K, Fukami J, Yoshimoto H, Ueda M, Suzuki J, Okamato M, et al. Evaluation of efficacy of betahistine on patients with vertigo by double blind test and discriminant analysis. Japanese Medical News (Overseas edition) 1967;121:4-6.
    1. Watanabe K, Fukami J, Yoshimoto H, Ueda M, Suzuki J. Evaluation of the effect of betahistine in Menière's disease by double-blind test and multivariate analysis. Jibiinkoka 1967;39(11):1237-50. - PubMed
Wilmot 1976 {published data only}
    1. Wilmot TJ, Menon GN. Betahistine in Menière's disease. Journal of Laryngology and Otology 1976;90:833-40. - PubMed
Wolfson 1967 {published data only}
    1. Wolfson RJ, Myers D, Schlosser WD. Menière's disease treatment with betahistine. Eye, Ear, Nose, Throat Monthly 1967;46:891-6.

References to studies awaiting assessment

Pedersen 1978 {published data only}
    1. Pedersen CB, Kampmann JP. Treatment of Meniere's disease with particular reference to the use of betahistine. Ugeskrift for Laeger 1978;140(48):3004-6. - PubMed

Additional references

Alford 1972
    1. Alford BR. Menière’s disease: criteria for diagnosis and evaluation of therapy for reporting. Report of subcommittee on equilibrium and its measurement. Transactions of the American Academy of Ophthalmology and Otolaryngology 1972;76:1462-4. - PubMed
Beeson 1963
    1. Beeson PB, McDermott W. Cecil-Loeb Textbook of Medicine. Philadelphia: WB Saunders Company, 1963.
Committee 1995
    1. Committee on Hearing and Equilibrium. Guidelines for the diagnosis and evaluation of therapy in Menière’s disease. Otolaryngology - Head and Neck Surgery 1995;113:181-5. - PubMed
Friberg 1984
    1. Friberg U, Stahle J, Svedberg A. The natural course of Menière's disease. Acta Otolaryngologica 1984;406(Suppl):72-7. - PubMed
Hallpike 1938
    1. Hallpike C, Cairns H. Observations on the pathology of Menière’s syndrome. Journal of Laryngology and Otology 1938;53:625-55. - PMC - PubMed
Handbook 2009
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated February 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
Martindale 1996
    1. Reynolds JEF. Martindale: The Extra Pharmacopoeia. London: Royal Pharmaceutical Society, 1996.
Martinez 1972
    1. Martinez DM. The effect of Serc on the circulation of the inner ear in experimental animals. Acta Otolaryngologica 1972;Suppl 305:29-46. - PubMed
Moffat 1997
    1. Moffat DA, Ballagh RH. Menière’s Disease. In: Kerr A G, Booth J B, editors(s). Scott-Brown’s Otolaryngology. 6th edition. Vol. 3. Oxford: Butterworth-Heinemann, 1997:3/19/1-50. [ISBN 0 7506 0597 9]
Pearson 1985
    1. Pearson BW, Brackmann DE. Committee on hearing and equilibrium guidelines for reporting treatment results in Menière’s disease. Otolaryngology - Head and Neck Surgery 1985;93:578-81. - PubMed
Ruckenstein 1999
    1. Ruckenstein MJ, Harrison RV. Cochlear pathology in Menière's disease. In: Harris JP, editors(s). Menière's Disease. The Hague, The Netherlands: Kugler Publications, 1999:195-202.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. - PubMed
Silverstein 1989
    1. Silverstein H, Smouha E, Jones R. Natural history versus surgery for Menière’s disease. Otolaryngology - Head and Neck Surgery 1989;100:6-16. - PubMed
Solvay 1998
    1. Solvay Healthcare Limited. Serc8, Serc16. In: ABPI Compendium of Data Sheets. 1999-2000 edition. London: Datapharm Publications Ltd, 1999:1629.
Stahle 1978
    1. Stahle J, Stahle C, Arenberg IK. Incidence of Ménière's disease. Archives of Otolaryngology 1978;104(2):99-102. [629706] - PubMed
Timmerman 1994
    1. Timmerman H. Pharmacotherapy of vertigo: any news to be expected? Acta Otolaryngologica 1994;Suppl 513:28-32. - PubMed
Watanabe 1983
    1. Watanabe I. Incidence of Meniere's disease, including some other epidemiological data. In: Oosterveld WJ, editors(s). Meniere's Disease: A Comprehensive Appraisal. Chichester: John Wiley and Sons Ltd, 1983:9-23.
Williams 1964
    1. Williams HL. Comments on Menière's disease. Postgraduate Medicine 1964;36:274-7. - PubMed

References to other published versions of this review

James 2000
    1. James AL, Burton MJ. Betahistine for Menière's disease or syndrome. In: Proceedings of the 4th International Symposium on Menière's Disease. The Hague, Netherlands: Kugler Publications, 2000.

Publication types

MeSH terms